Filamon

Filamon represents a high-impact life sciences opportunity aligned with Wahl Citadel's focus on asymmetric investments with transformational upside potential. The company is developing next-generation therapies targeting age-related chronic diseases, with a particular focus on inflammatory degenerative conditions and oncology.

Positioned within a rapidly expanding global biotech sector, Filamon's research pipeline addresses some of the largest unmet medical needs associated with ageing populations and chronic disease burden. With significant commercial potential across multiple therapeutic applications, the business is advancing toward a planned IPO in September–October 2026, where Wahl Citadel has participated as a cornerstone investor.